BioLingus

BioLingus

Biotechnology

Company website
Foundation year

2015

About

Biotechnology company spearheading the development of oral (specifically, sublingual) delivery of peptides and proteins.

The delivery of peptides or proteins, such as insulin, in a non-invasive way (i.e. without needles or injections) is a very challenging endeavor from a scientific and technical perspective.

Since our inception, company have focused on developing an alternative approach, known as sublingual delivery.

 

_____________________________

The number of employees:

10-50

_____________________________

Headquarters:

Grossmatt 6 CH-6052 Hergiswil NW Switzerland


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.